Respiratory tract infections and the fluoroquinolones of the latest generations
- Autores: Nonikov VE1, Nonikov V1
-
Afiliações:
- Edição: Nº 4 (2010)
- Páginas: 38-41
- Seção: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278292
- ID: 278292
Citar
Texto integral
Resumo
This article presents data for the etiology of pneumonia and exacerbations of chronic bronchitis/chronic obstructive pulmonary disease. The spectrum of respiratory fluoroquinolones (levofloxacin, moxifloxacin), indications for their use, treatment regimens and dosage regimens are considered. The author presents own data for the long-term use of levofloxacin in the treatment of lower respiratory tract infections. Various schemes of levofloxacin use, including step-down therapy are expressed. The effectiveness of levofloxacin alone and in combination with carbapenems in the treatment of critically severe pneumonia is presented.
Bibliografia
- Белоусов Ю.Б., Шатунов С.М. Антибактериальная химиотерапия. М., 2001. 473 с.
- Ноников В.Е., Маликов В.Е., Евдокимова С.А. и др. Антибиотики в пульмонологии // Кремлевская медицина - клинический вестник. 2005. № 1. С. 20-23.
- Практическое руководство по антиинфекционной химиотерапии / Под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. Смоленск, 2007. 464 с.
- Bartlett J.G. 2005-2006 Pocket Book of Infectious Disease Therapy. Lippincott Williams & Wilkins. 2004. 349 с.
- Гилберт Д.Н., Моллеринг Р.С., Эллиопулос Д.М. и др. Сэнфордский спавочник: антимикробная терапия. М., 2009. 288 с.
- Wilson J, Estes L. Mayo Clinic Antimicrobial Therapy. Mayo Clinic Scientific Press 2008:324.